

## H I G H L I G H T S

### CONTACTS & KEY INFORMATION

<b>Headquarters</b>	3 rue de Verdun-Bat G 78590 Noisy le Roi, France Tel: +33 161 06 19 92 Fax: +33 130 56 50 35
<b>Website</b>	www.art-stent.com
<b>Employees</b>	7
<b>Sector</b>	Cardiovascular stenting
<b>Founded</b>	November 2002
<b>Core Technology</b>	<b>Bioresorbable stents</b> that facilitate the body's natural arterial remodeling process
<b>Contact</b>	Ronald C. Trahan, APR Ronald Trahan Associates, Inc. (508) 359-4005, x108

### BOARD OF DIRECTORS

#### Patrick Sabaria, CEO, ART

Former Vice President Europe of J&J Interventional Systems; he launched in Europe the first coronary stents to hit the market; MS degree in Biology and Immunology.

#### J. F. Cornhill, PhD

Currently the Director of the Institute of Biomedical Engineering at the University of Oxford; founding Director of the Lerner Research Institute at the Cleveland Clinic.

#### Christophe Douat, MBA, MS

Director of Investments at Matignon Technologies, one of the largest European funds focusing on Medtech; formerly with Boston Consulting Group (BCG).

#### Antoine Lafont, MD, PhD

Head of the Interventional Cardiology Department at the Georges Pompidou Hospital in Paris; Chairman of the Interventional Cardiology Group of the European Society of Cardiology (ESC).

#### Michel Vert, PhD

Fmr. Director, Center of Research for Artificial Biopolymers at French research institute, CNRS.

#### Eric Viaud, MS

Chairman and CEO of Gene Signal; 20 years in pharma and medical industries (BASF, Synthelabo, Medtronic) in Research, Clinical, Licensing and Marketing positions.

▶ **Arterial Remodeling Technologies (“ART”) is developing *bioresorbable peripheral and coronary polymer stents* that promote the natural remodeling of an injured artery after angioplasty.** The Company's technology is based on intellectual property originating from three esteemed institutions: the **Cleveland Clinic**; the French national research institute, **C.N.R.S.** (Centre National de Recherche Scientifique), Montpellier, France; and, **Necker University**, Paris. ART has raised €10 million (\$14.2 million) from VCs **Matignon Technologies** and **SGAM Alternative Investments**.

▶ **ART's bioresorbable stents are designed to dismantle *in vivo* over an *optimized* time horizon, thus allowing the body's own natural arterial remodeling process to occur, unrestricted by the presence of a permanent metallic stent.** The Company's proprietary, polymer-based technology promotes the natural remodeling of an injured and/or diseased artery after angioplasty or other similar procedures. ART has established proof-of-concept with preclinical implantation studies in iliac and coronary models that can be applied and adapted to a wide variety of stent designs.

▶ **ART's platform benefits from Pr. Michel Vert's 30 years of trade secret *savoir-faire* in biodegradable polymers.** The Company's innovative stents consist of proprietary polymers that are non-inflammatory, biocompatible, hemocompatible, mechanically strong and biodegradable. These novel polymers are developed in conjunction with one of the world's leading authorities in polymer chemistry, Pr. Vert, who is Former Director of the Research Center for Artificial Biopolymers at France's National Center for Scientific Research (Centre National de Recherche Scientifique/C.N.R.S.).

▶ **Application of ART's novel polymer technology to the development of its bioresorbable stents gives them several distinct advantages over drug-eluting stents (DES).** The next-generation-approach being pursued by ART is to achieve temporary stenting of a traumatized angioplasty site, for example, to (a) prevent acute and chronic recoil; (b) allow the arterial wall to remodel through the use of a stent that dismantles; and (c) allow natural physiological healing and remodeling processes to proceed.

▶ **ART is led by co-founder and CEO Patrick Sabaria, who initiated commercialization efforts for the world's first approved-for-marketing stent: the *Palmaz stent*.** As former Vice President, Europe, for J&J Interventional Systems and Head of its European cardiovascular stent division, Mr. Sabaria was responsible for introducing the Palmaz stent, which is recognized as one of the most important medical devices in history.

### ART's Bioresorbable Stents Dismantle *In Vivo*

“Just three years ago bioabsorbable stents seemed to be more of a *nice to have* than a *need to have*. After all, drug-eluting stents (DES) were seen as the answer to restenosis and showed very minimal risks to patient safety. Johnson & Johnson and Boston Scientific had the clear lead in introducing *Cypher* and *Taxus*, respectively, to the interventional community, with **Medtronic, Guidant, and Abbott Laboratories** bringing up the rear. Then in September 2006 at the World Congress of Cardiology meeting...DES were linked to a four-letter word—**clot**. The very same device that staved off restenosis was delivering a new danger—late-stage thrombosis. Furthermore, clinicians and corporate executives once again began asking a question they thought they had answered: **why deploy a permanent implant on a short-term mission of clearing a coronary artery?**” (Source: ‘Bioabsorbable Stents’, *Start-Up*, January 2007) **ART's stent is designed to provide the requisite initial acute mechanical scaffolding but, as it dismantles due to bioresorbability, the possibility of arterial remodeling returns to the artery.**